Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical ...

The proportion of participants achieving HbA1c DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head comparison with semaglutide in ...

Midlife weight gain is a persistent challenge for many women, but emerging research suggests hormone therapy may enhance response to glucagon-like peptide-1 (GLP-1)–based treatments.

Development of the latest class of incretin-based therapeutics for diabetes and obesity has been heralded as a major step ...

Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.

Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...

Why is the Supreme Court’s directive to notify a new Saranda wildlife sanctuary important for your UPSC exam? What ...

The cornerstone of this strategic offensive is the drug Tirzepatide, a compound already achieving blockbuster status in other global markets for treating Type 2 diabetes and obesity. Under the brand ...

Cipla has partnered with Eli Lilly and Company (India) to distribute & promote Tirzepatide in India under a second brand name, Yurpeak, aiming to expand access to innovative treatments for chronic ...

US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...

Shares of Cipla fell more than 3 per cent on Friday after the drugmaker announced a partnership with US pharmaceutical major ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...